{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:45Z","timestamp":1791644805804,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jcjo.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T16:52:36Z","timestamp":1678639956000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Advances in conjunctival melanoma: clinical features, diagnostic modalities, staging, genetic markers, and management"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2209-6296","authenticated-orcid":false,"given":"Jennifer S.","family":"Zeiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4284","authenticated-orcid":false,"given":"Lauren A.","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-3632","authenticated-orcid":false,"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2023.02.003_bib0001","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0039-6257(97)00122-7","volume":"42","author":"Seregard","year":"1998","journal-title":"Conjunctival melanoma. Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2016.09.034","article-title":"Conjunctival tumors in 5002 cases. Comparative analysis of benign versus malignant counterparts. 2016 James D. Allen lecture","volume":"173","author":"Shields","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1755-3768.1992.tb08566.x","article-title":"Conjunctival malignant melanoma in Sweden 1969\u201391","volume":"70","author":"Seregard","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1167\/iovs.04-0344","article-title":"Conjunctival melanoma in the Netherlands: a nationwide study","volume":"46","author":"Missotten","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0005","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/bjophthalmol-2017-311530","article-title":"Population-based incidence of conjunctival tumours in Olmsted County, Minnesota","volume":"102","author":"Dalvin","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/aos.13100","article-title":"Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0007","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","article-title":"Time trends in the incidence of conjunctival melanoma in Sweden","volume":"93","author":"Triay","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0008","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/ICO.0000000000002449","article-title":"Conjunctival melanoma: outcomes based on age at presentation in 629 patients at a single ocular oncology center","volume":"40","author":"Dalvin","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0009","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bjo.77.10.624","article-title":"Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases","volume":"77","author":"De Potter","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CMR.0b013e3282fafd21","article-title":"Sentinel lymph node biopsy guidelines for conjunctival melanoma","volume":"18","author":"Tuomaala","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2016.5544","article-title":"Clinical features differentiating benign from malignant conjunctival tumors in children","volume":"135","author":"Shields","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0012","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/APO.0000000000000343","article-title":"Conjunctival melanoma: outcomes based on the American Joint Committee on Cancer Clinical Classification (8th edition) of 425 patients at a single ocular oncology center","volume":"10","author":"Shields","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0013","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0002-9394(14)75147-5","article-title":"Ocular Melanoma Task Force report","volume":"90","author":"Graham","year":"1980","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0014","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/IOP.0000000000001624","article-title":"Conjunctival melanoma: features and outcomes based on the Fitzpatrick skin type in 540 patients at a single ocular oncology center","volume":"36","author":"Shields","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41433-021-01508-y","article-title":"Conjunctival melanoma: outcomes based on tumour origin in 629 patients at a single ocular oncology centre","volume":"36","author":"Pacheco","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/2320-3897.130549","article-title":"Ultrasound biomicroscopy: an overview","volume":"2","author":"Bhatt","year":"2014","journal-title":"J Clin Ophthalmol Res"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/17469899.2014.921119","article-title":"Management of conjunctival malignant melanoma: a review and update","volume":"9","author":"Wong","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0018","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ophtha.2010.11.011","article-title":"Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases","volume":"118","author":"Bianciotto","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0161-6420(91)32270-X","article-title":"Magnetic resonance imaging of choroidal melanoma with and without gadolinium contrast enhancement","volume":"98","author":"Bond","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5539\/gjhs.v4n1p253","article-title":"Intra-orbital malignant melanoma: role of MR imaging (a case report and literature review)","volume":"4","author":"Uduma","year":"2011","journal-title":"Glob J Health Sci"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0021","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/archopht.116.7.897","article-title":"Evaluation of imaging techniques for detection of extraocular extension of choroidal melanoma","volume":"116","author":"Scott","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0022","series-title":"AJCC cancer staging manual","first-page":"541","article-title":"Malignant melanoma of the conjunctiva","author":"Edge","year":"2010"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0023","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/IOP.0b013e31828ecfdf","article-title":"American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes","volume":"29","author":"Shields","year":"2013","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0024","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1177\/1120672120970393","article-title":"Conjunctival melanoma: risk factors for recurrent or new tumor in 540 patients at a single ocular oncology center","volume":"31","author":"Vaidya","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0025","first-page":"109","article-title":"Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes\u2014the 2017 J. Donald M. Gass Lecture","volume":"6","author":"Shields","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0026","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00002341-200111000-00010","article-title":"Sentinel lymph node biopsy for conjunctival melanoma","volume":"17","author":"Esmaeli","year":"2001","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0027","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ophtha.2003.11.001","article-title":"Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy","volume":"111","author":"Tuomaala","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0028","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0029","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41416-018-0046-5","article-title":"NF1 mutations in conjunctival melanoma","volume":"118","author":"Scholz","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100971","article-title":"Conjunctival melanoma: new insights in tumour genetics and immunology, leading to new therapeutic options","volume":"86","author":"Brouwer","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0031","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.2013.312","article-title":"TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours","volume":"109","author":"Griewank","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0032","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Pleasance","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0033","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/bjo.2010.183939","article-title":"Expression of HSP 90, PTEN and bcl-2 in conjunctival melanoma","volume":"95","author":"Westekemper","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0034","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2022.01.016","article-title":"Mutational landscape and outcomes of conjunctival melanoma in 101 patients","volume":"129","author":"Lally","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0035","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/bjophthalmol-2020-317405","article-title":"Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features","volume":"105","author":"van Ipenburg","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0036","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3390\/ijms22115784","article-title":"Molecular genetics of conjunctival melanoma and prognostic value of TERT promoter mutation analysis","volume":"22","author":"van Poppelen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0037","doi-asserted-by":"crossref","first-page":"54722","DOI":"10.18632\/oncotarget.18039","article-title":"PD-L1\/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0038","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CMR.0b013e32832ccd09","article-title":"Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma","volume":"20","author":"P\u00f3pulo","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0039","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1878-0261.12050","article-title":"NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics","volume":"11","author":"Cirenajwis","year":"2017","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.jcjo.2023.02.003_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-019-0555-7","article-title":"Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series","volume":"7","author":"Finger","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0041","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/bjc.2015.345","article-title":"Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol","volume":"113","author":"Shen","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0042","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.3390\/cancers13225691","article-title":"Small but challenging conjunctival melanoma: new insights, paradigms and future perspectives","volume":"13","author":"Nahon-Est\u00e8ve","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0043","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/bjo.78.7.520","article-title":"Orbital exenteration in 95 cases of primary conjunctival malignant melanoma","volume":"78","author":"Paridaens","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0044","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamaophthalmol.2020.0522","article-title":"Controlling conjunctival melanoma\u2014to infinity and beyond","volume":"138","author":"Shields","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00417-009-1189-0","article-title":"Interferon \u03b1 for the treatment of melanocytic conjunctival lesions","volume":"248","author":"Herold","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0046","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00417-004-1080-y","article-title":"Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years\u2019 experience","volume":"243","author":"Kurli","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0047","first-page":"51","article-title":"A case of conjunctival malignant melanoma treated with subconjunctival injection of interferon beta\u2014efficacy and side effects","volume":"110","author":"Fujioka","year":"2006","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0048","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.08.027","article-title":"Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex","volume":"145","author":"Finger","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0049","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/bjo.74.10.615","article-title":"Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva","volume":"74","author":"Lommatzsch","year":"1990","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/IOP.0b013e31818be098","article-title":"Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva","volume":"24","author":"Hsu","year":"2008","journal-title":"Opthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0051","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00417-005-0093-5","article-title":"Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma","volume":"244","author":"Wuestemeyer","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0052","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF00448801","article-title":"Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population","volume":"234","author":"Norregaard","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0053","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/IOP.0000000000000833","article-title":"Conjunctival melanoma responsive to combined systemic BRAF\/MEK inhibitors","volume":"33","author":"Dagi Glass","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0054","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4172\/2155-9570.1000322","article-title":"Conjunctival melanoma and BRAF inhibitor therapy","volume":"5","author":"Pahlitzsch","year":"2014","journal-title":"J Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000497473","article-title":"Dabrafenib and trametinib for BRAF-mutated conjunctival melanoma","volume":"6","author":"Kim","year":"2019","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0056","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0057","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaophthalmol.2017.2279","article-title":"Pembrolizumab for recurrent conjunctival melanoma","volume":"135","author":"Kini","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.02.003_bib0058","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","article-title":"Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma","volume":"136","author":"Sagiv","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T12:17:34Z","timestamp":1728994654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418223000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0008418223000431"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.02.003","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in conjunctival melanoma: clinical features, diagnostic modalities, staging, genetic markers, and management","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}